Clinical Trial Detail

NCT ID NCT04265872
Title Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Recruitment Not yet recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Baylor Research Institute
Indications

triple-receptor negative breast cancer

Therapies

Bortezomib + Cisplatin + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.